Pharmaceutical cost-containment policy: Experiences in Shanghai, China

Health Policy and Planning

Volumn 16, Issue SUPPL. 2, 2001, Pages 4-9

  Hu, Shanlian ^a   Chen, Wen ^a   Cheng, Xiaoming ^a   Chen, Keyong ^b   Zhou, Haiyang ^b   Wang, Longxing ^b  

^a FUDAN UNIVERSITY   (China)

^b University of Shanghai   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; DRUG; HERBACEOUS AGENT; PENICILLIN DERIVATIVE;

ARTICLE; CHINA; COST CONTROL; DEVELOPING COUNTRY; DRUG COST; DRUG INDUSTRY; HEALTH CARE FINANCING; HEALTH CARE PLANNING; HEALTH CARE POLICY; OUTPATIENT CARE;

EID: 0035704113     PISSN: 02681080     EISSN: None     Source Type: Journal    
DOI: 10.1093/heapol/16.suppl_2.4     Document Type: Article

References (14)

1. Lessons from international experience in controlling pharmaceutical expenditure. II: Influencing doctors
2. Lessons from international experience in controlling pharmaceutical expenditure. III: Regulating industry
3. Drug policy in China: Pharmaceutical distribution in rural areas
4. Future European health care: Cost containment, health care reform and scientific progress in drug research
5. Lessons from international experience in controlling pharmaceutical expenditure. I: Influencing patients
6. International pharmaceutical spending controls: France, Germany, Sweden, and the United Kingdom
7. Health policy versus industrial policy in the pharmaceutical sector: The case of Canada
8. Issues on pharmaceutical expenditure in China
9. The selection of essential drugs. Report of a WHO Expert Committee
10. Total health expenditure in China (1978-1995)
11. The impacts of hospital revenue capping policy on development of pharmaceutical industry